Hofseth BioCare（HOFB.F）株式概要Hofseth BioCare ASAは、ノルウェー、英国、フランス、ベルギー、イタリア、ドイツ、ヨーロッパ、日本、アジア、米国において、ヒト用およびペット用の健康栄養製品の製造に従事している。 詳細HOFB.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6リスク分析過去5年間で収益は年間3%減少しました。 株式の流動性は非常に低い 意味のある時価総額がありません ( $72M )すべてのリスクチェックを見るHOFB.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.1779.2% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-139m1b2016201920222025202620282031Revenue NOK 1.0bEarnings NOK 190.3mAdvancedSet Fair ValueView all narrativesHofseth BioCare ASA 競合他社ImmuCellSymbol: NasdaqCM:ICCCMarket cap: US$89.2mHeron TherapeuticsSymbol: NasdaqCM:HRTXMarket cap: US$79.2mCoya TherapeuticsSymbol: NasdaqCM:COYAMarket cap: US$126.4mGossamer BioSymbol: NasdaqGS:GOSSMarket cap: US$83.8m価格と性能株価の高値、安値、推移の概要Hofseth BioCare過去の株価現在の株価NOK 0.1752週高値NOK 0.1752週安値NOK 0.095ベータ0.531ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化-81.28%IPOからの変化-51.17%最新ニュースお知らせ • Apr 14Hofseth BioCare ASA Publishes Clinical Trial Results of Omego Full Spectrum OmegasHofseth BioCare ASA announced the publication of its head-to-head clinical trial results with its patented, full spectrum omegas brand, OmeGo. The trial showed that OmeGo increased the Omega 3 Index (O3I) by over 70% after 14 weeks, over and above a popular omega-3 supplement brand. It was also markedly more effective at reducing inflammatory markers (hsCRP, TNFa and IL-6) which are closely related to the development of ill health. The omega-3 index (O3I) assesses the level of EPA and DHA in red blood cells – a measure known to correlate well with the overall amount of omega-3 in the body. An optimal O3I level has been shown to reduce the risk of death from any cause by around 35%. Indeed, a higher O3I is associated with a reduced risk of major killers including cardiovascular and metabolic disease and cancer. Notably, OmeGo contains 2.5 times less EPA & DHA than the omega-3 supplement comparator used in this study. However, its natural food matrix significantly enhances OmeGo’s bioavailability. Hence its full spectrum profile better replicates the well-known health benefits associated with regularly eating fish. The success of this clinical study directly challenges the prevailing market assumption that higher-dose concentrated fish oils deliver greater health benefits. This represents a paradigm shift in how omega potency is viewed in the nutraceuticals market.お知らせ • Dec 04Hofseth BioCare ASA, Annual General Meeting, May 22, 2026Hofseth BioCare ASA, Annual General Meeting, May 22, 2026.お知らせ • Dec 03+ 4 more updatesHofseth BioCare ASA to Report Fiscal Year 2025 Final Results on Mar 27, 2026Hofseth BioCare ASA announced that they will report fiscal year 2025 final results on Mar 27, 2026お知らせ • Nov 21Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 29.999999 million.Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 29.999999 million. Security Name: Shares Security Type: Common Stock Securities Offered: 16,666,666 Price\Range: NOK 1.8 Transaction Features: Rights Offeringお知らせ • Oct 27+ 1 more updateHofseth BioCare ASA announced that it expects to receive NOK 103.399999 million in funding from GCI CSS (Hofseth & Nevera) LLCHofseth BioCare ASA announced private placement of 57,444,444 common shares at a price of NOK 1.80 for gross proceeds of NOK 103,399,999.2 on October 27, 2025. The transaction includes participation from Guy Urquhart for 55,444,444 Shares, for gross proceeds of approximately NOK 99,799,999.2 and GCI Hofseth Llc. for 2,000,000 shares for gross proceeds of approximately NOK 3,600,000. The transaction is expected to close on October 30, 2025. The transaction is approved by board of directors of the company and the issuance of shares is subject to Board resolution to allocate shares, Registration of the share capital increase, Satisfaction of contingencies related to the divestment of shares in AecorBio. Upon completion of the Private Placement, the Company will have a share capital of NOK 48,289,214.40, divided by 482,892,140 Ordinary Shares and 16,000,000 unlisted preference shares in Class B held by Hofseth International AS, each with a par value of NOK 0.01.お知らせ • Sep 10Hofseth Biocare ASA Releases a Whitepaper Demonstrating How Its Bioactive Peptide Ingredient ProGo®? uniquely Provides Complete GLP-1 SupportHofseth Biocare ASA released a whitepaper demonstrating how its bioactive peptide ingredient ProGo®? uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs to be protected to optimize the benefits of weight loss and support a healthy metabolism. ProGo®? addresses these needs through its unique triple action properties: highly absorbable protein with a complete amino acid profile to help build muscle; antioxidant and anti-inflammatory bioactivity to protect muscle health; inhibition of Activin A and Myostatin, negative regulators of muscle mass. ProGo®? is the only commercially available bioactive peptide health ingredient that is both a GLP-1 RA (Receptor Agonist) and has a targeted mode of action for muscle protection via inhibition of Myostatin & Activin A. A fully traceable, high-quality nutritional supplement comprised of hydrolysed peptides and collagen, it has a complete amino acid profile that includes high levels of branched chain amino acids (BCAA) - essential for muscle formation and health. ProGo®? also has a higher bioavailability than other peptides on the market, as the smaller average size of peptides makes them easier for the body to digest.最新情報をもっと見るRecent updatesお知らせ • Apr 14Hofseth BioCare ASA Publishes Clinical Trial Results of Omego Full Spectrum OmegasHofseth BioCare ASA announced the publication of its head-to-head clinical trial results with its patented, full spectrum omegas brand, OmeGo. The trial showed that OmeGo increased the Omega 3 Index (O3I) by over 70% after 14 weeks, over and above a popular omega-3 supplement brand. It was also markedly more effective at reducing inflammatory markers (hsCRP, TNFa and IL-6) which are closely related to the development of ill health. The omega-3 index (O3I) assesses the level of EPA and DHA in red blood cells – a measure known to correlate well with the overall amount of omega-3 in the body. An optimal O3I level has been shown to reduce the risk of death from any cause by around 35%. Indeed, a higher O3I is associated with a reduced risk of major killers including cardiovascular and metabolic disease and cancer. Notably, OmeGo contains 2.5 times less EPA & DHA than the omega-3 supplement comparator used in this study. However, its natural food matrix significantly enhances OmeGo’s bioavailability. Hence its full spectrum profile better replicates the well-known health benefits associated with regularly eating fish. The success of this clinical study directly challenges the prevailing market assumption that higher-dose concentrated fish oils deliver greater health benefits. This represents a paradigm shift in how omega potency is viewed in the nutraceuticals market.お知らせ • Dec 04Hofseth BioCare ASA, Annual General Meeting, May 22, 2026Hofseth BioCare ASA, Annual General Meeting, May 22, 2026.お知らせ • Dec 03+ 4 more updatesHofseth BioCare ASA to Report Fiscal Year 2025 Final Results on Mar 27, 2026Hofseth BioCare ASA announced that they will report fiscal year 2025 final results on Mar 27, 2026お知らせ • Nov 21Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 29.999999 million.Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 29.999999 million. Security Name: Shares Security Type: Common Stock Securities Offered: 16,666,666 Price\Range: NOK 1.8 Transaction Features: Rights Offeringお知らせ • Oct 27+ 1 more updateHofseth BioCare ASA announced that it expects to receive NOK 103.399999 million in funding from GCI CSS (Hofseth & Nevera) LLCHofseth BioCare ASA announced private placement of 57,444,444 common shares at a price of NOK 1.80 for gross proceeds of NOK 103,399,999.2 on October 27, 2025. The transaction includes participation from Guy Urquhart for 55,444,444 Shares, for gross proceeds of approximately NOK 99,799,999.2 and GCI Hofseth Llc. for 2,000,000 shares for gross proceeds of approximately NOK 3,600,000. The transaction is expected to close on October 30, 2025. The transaction is approved by board of directors of the company and the issuance of shares is subject to Board resolution to allocate shares, Registration of the share capital increase, Satisfaction of contingencies related to the divestment of shares in AecorBio. Upon completion of the Private Placement, the Company will have a share capital of NOK 48,289,214.40, divided by 482,892,140 Ordinary Shares and 16,000,000 unlisted preference shares in Class B held by Hofseth International AS, each with a par value of NOK 0.01.お知らせ • Sep 10Hofseth Biocare ASA Releases a Whitepaper Demonstrating How Its Bioactive Peptide Ingredient ProGo®? uniquely Provides Complete GLP-1 SupportHofseth Biocare ASA released a whitepaper demonstrating how its bioactive peptide ingredient ProGo®? uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs to be protected to optimize the benefits of weight loss and support a healthy metabolism. ProGo®? addresses these needs through its unique triple action properties: highly absorbable protein with a complete amino acid profile to help build muscle; antioxidant and anti-inflammatory bioactivity to protect muscle health; inhibition of Activin A and Myostatin, negative regulators of muscle mass. ProGo®? is the only commercially available bioactive peptide health ingredient that is both a GLP-1 RA (Receptor Agonist) and has a targeted mode of action for muscle protection via inhibition of Myostatin & Activin A. A fully traceable, high-quality nutritional supplement comprised of hydrolysed peptides and collagen, it has a complete amino acid profile that includes high levels of branched chain amino acids (BCAA) - essential for muscle formation and health. ProGo®? also has a higher bioavailability than other peptides on the market, as the smaller average size of peptides makes them easier for the body to digest.お知らせ • Sep 04Hofseth BioCare ASA Appoints Paul Bruhn as Head of New Business DevelopmentHofseth BioCare ASA announced the appointment of Paul Bruhn as Head of New Business Development. Mr. Bruhn has over 25 years’ experience in healthcare and the medical nutrition space spanning Novartis Medical Nutrition and Nestle Health Science. He has been leading businesses across multiple geographies including Japan, Korea, India, Middle East, Singapore, Canada, Switzerland and Australia and hence has an excellent overlap with corporates focused on developing the next generation of products targeting clinical nutrition and consumer healthcare. Mr. Bruhn has significant experience working within the medical nutrition, VMS and meal replacement categories, across multiple channels.お知らせ • Nov 11Hofseth BioCare ASA, Annual General Meeting, May 23, 2025Hofseth BioCare ASA, Annual General Meeting, May 23, 2025.お知らせ • Nov 09Hofseth BioCare ASA to Report Q4, 2025 Results on Feb 13, 2026Hofseth BioCare ASA announced that they will report Q4, 2025 results at 12:00 PM, Central European Standard Time on Feb 13, 2026お知らせ • Nov 08+ 3 more updatesHofseth BioCare ASA to Report First Half, 2025 Results on Aug 22, 2025Hofseth BioCare ASA announced that they will report first half, 2025 results on Aug 22, 2025お知らせ • Oct 22Hofseth Biocare Asa Announces Resignation of Christel Elise Kanli as CFOHofseth BioCare ASA announced that Christel Elise Kanli has decided to step down as Chief Financial Officer (CFO) of the company to pursue opportunities outside of the company.お知らせ • Mar 15Hofseth BioCare ASA Announces Board ChangesHofseth BioCare ASA announced Kristin Fjellby Grung, Chair of the Board has informed the Board of Directors that she will resign from the position on 31 March 2024, as she will assume a position as judge in the District Court of Møre and Romsdal and will therefore not be able to continue to serve in the position as Chair of the Board. Grung has been a member of the Board of Directors since December 2020, and assumed the position as Chair in April 2022. The Board would like to thank Grung for her services for Hofseth BioCare in this period. Appointment of a new Chair of the Board will be proposed to the Company's annual general meeting, to be held on 10 May 2024. In the interim period, Roger Hofseth will function as the Chair of the Board of Directors.お知らせ • Nov 14+ 5 more updatesHofseth BioCare ASA to Report Q4, 2024 Results on Feb 14, 2025Hofseth BioCare ASA announced that they will report Q4, 2024 results on Feb 14, 2025お知らせ • May 31Hofseth Biocare ASA Announces the Online Publication of Its AbstractHofseth Biocare ASA announced the online publication of its abstract titled "Antiproliferative activity of marine-derived oligopeptides combined with androgen receptor inhibition in preclinical cancer models" (Journal of Clinical Oncology 41, 2023, supplement 16; abstract # e15186) ahead of the annual ASCO meeting in Chicago, June 2-5, 2023. This work by HBC represents the final phase of invitro research which has identified the lead peptide candidates, FT-002 and FT-005, for organoid and in vivo prostate cancer research in combination with standard of care therapy, planned to commence during H2 2023. Prostate cancer remains the most commonly diagnosed cancer in men. Whilst most cases do not shorten life expectancy, advanced prostate cancer remains largely incurable. Hormone therapy remains the cornerstone of treatment however eventually tumours find ways of overcoming treatment and start to grow and spread. One important route of tumour escape is via hijacking cellular iron metabolism. In preclinical models, including those published in the ASCO abstract, FT-002 and FT-005 have shown a consistent ability to modulate iron metabolism within tumour cells to both enhance tumour cell sensitivity to standard of care hormone therapy as well as reversing resistance to standard hormone therapy.お知らせ • Nov 18+ 4 more updatesHofseth BioCare ASA to Report Fiscal Year 2022 Results on Mar 31, 2023Hofseth BioCare ASA announced that they will report fiscal year 2022 results on Mar 31, 2023株主還元HOFB.FUS BiotechsUS 市場7D0%4.0%-2.3%1Yn/a34.1%21.2%株主還元を見る業界別リターン: HOFB.FがUS Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: HOFB.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is HOFB.F's price volatile compared to industry and market?HOFB.F volatilityHOFB.F Average Weekly Movementn/aBiotechs Industry Average Movement10.6%Market Average Movement7.2%10% most volatile stocks in US Market16.7%10% least volatile stocks in US Market3.1%安定した株価: HOFB.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のHOFB.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト200075Jon Odegardwww.hofsethbiocare.comHofseth BioCare ASA社は、ノルウェー、英国、フランス、ベルギー、イタリア、ドイツ、ヨーロッパ、日本、アジア、米国において、人間とペット用の健康栄養製品の製造に従事している。同社の製品には、新鮮な丸ごとのサーモンに自然に含まれる脂肪酸とオメガのフルスペクトルを提供するサーモンオイルOmeGo、体重管理と代謝のための生物活性ペプチドProGo、骨と関節の健康のためのカルシウムコラーゲン複合体CalGo、CollaGo、非水溶性タンパク質PetGoなどがある。同社は2000年に設立され、ノルウェーのオーレスンに本社を置いている。もっと見るHofseth BioCare ASA 基礎のまとめHofseth BioCare の収益と売上を時価総額と比較するとどうか。HOFB.F 基礎統計学時価総額US$71.93m収益（TTM）-US$13.78m売上高(TTM)US$26.35m2.7xP/Sレシオ-5.2xPER（株価収益率HOFB.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計HOFB.F 損益計算書（TTM）収益NOK 262.08m売上原価NOK 188.06m売上総利益NOK 74.02mその他の費用NOK 211.04m収益-NOK 137.02m直近の収益報告Jun 30, 2025次回決算日Nov 07, 2025一株当たり利益（EPS）-0.33グロス・マージン28.24%純利益率-52.28%有利子負債／自己資本比率84,946.8%HOFB.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/10/04 22:40終値2025/07/07 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Hofseth BioCare ASA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Jonas PeciulisNorne Securities AS
お知らせ • Apr 14Hofseth BioCare ASA Publishes Clinical Trial Results of Omego Full Spectrum OmegasHofseth BioCare ASA announced the publication of its head-to-head clinical trial results with its patented, full spectrum omegas brand, OmeGo. The trial showed that OmeGo increased the Omega 3 Index (O3I) by over 70% after 14 weeks, over and above a popular omega-3 supplement brand. It was also markedly more effective at reducing inflammatory markers (hsCRP, TNFa and IL-6) which are closely related to the development of ill health. The omega-3 index (O3I) assesses the level of EPA and DHA in red blood cells – a measure known to correlate well with the overall amount of omega-3 in the body. An optimal O3I level has been shown to reduce the risk of death from any cause by around 35%. Indeed, a higher O3I is associated with a reduced risk of major killers including cardiovascular and metabolic disease and cancer. Notably, OmeGo contains 2.5 times less EPA & DHA than the omega-3 supplement comparator used in this study. However, its natural food matrix significantly enhances OmeGo’s bioavailability. Hence its full spectrum profile better replicates the well-known health benefits associated with regularly eating fish. The success of this clinical study directly challenges the prevailing market assumption that higher-dose concentrated fish oils deliver greater health benefits. This represents a paradigm shift in how omega potency is viewed in the nutraceuticals market.
お知らせ • Dec 04Hofseth BioCare ASA, Annual General Meeting, May 22, 2026Hofseth BioCare ASA, Annual General Meeting, May 22, 2026.
お知らせ • Dec 03+ 4 more updatesHofseth BioCare ASA to Report Fiscal Year 2025 Final Results on Mar 27, 2026Hofseth BioCare ASA announced that they will report fiscal year 2025 final results on Mar 27, 2026
お知らせ • Nov 21Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 29.999999 million.Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 29.999999 million. Security Name: Shares Security Type: Common Stock Securities Offered: 16,666,666 Price\Range: NOK 1.8 Transaction Features: Rights Offering
お知らせ • Oct 27+ 1 more updateHofseth BioCare ASA announced that it expects to receive NOK 103.399999 million in funding from GCI CSS (Hofseth & Nevera) LLCHofseth BioCare ASA announced private placement of 57,444,444 common shares at a price of NOK 1.80 for gross proceeds of NOK 103,399,999.2 on October 27, 2025. The transaction includes participation from Guy Urquhart for 55,444,444 Shares, for gross proceeds of approximately NOK 99,799,999.2 and GCI Hofseth Llc. for 2,000,000 shares for gross proceeds of approximately NOK 3,600,000. The transaction is expected to close on October 30, 2025. The transaction is approved by board of directors of the company and the issuance of shares is subject to Board resolution to allocate shares, Registration of the share capital increase, Satisfaction of contingencies related to the divestment of shares in AecorBio. Upon completion of the Private Placement, the Company will have a share capital of NOK 48,289,214.40, divided by 482,892,140 Ordinary Shares and 16,000,000 unlisted preference shares in Class B held by Hofseth International AS, each with a par value of NOK 0.01.
お知らせ • Sep 10Hofseth Biocare ASA Releases a Whitepaper Demonstrating How Its Bioactive Peptide Ingredient ProGo®? uniquely Provides Complete GLP-1 SupportHofseth Biocare ASA released a whitepaper demonstrating how its bioactive peptide ingredient ProGo®? uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs to be protected to optimize the benefits of weight loss and support a healthy metabolism. ProGo®? addresses these needs through its unique triple action properties: highly absorbable protein with a complete amino acid profile to help build muscle; antioxidant and anti-inflammatory bioactivity to protect muscle health; inhibition of Activin A and Myostatin, negative regulators of muscle mass. ProGo®? is the only commercially available bioactive peptide health ingredient that is both a GLP-1 RA (Receptor Agonist) and has a targeted mode of action for muscle protection via inhibition of Myostatin & Activin A. A fully traceable, high-quality nutritional supplement comprised of hydrolysed peptides and collagen, it has a complete amino acid profile that includes high levels of branched chain amino acids (BCAA) - essential for muscle formation and health. ProGo®? also has a higher bioavailability than other peptides on the market, as the smaller average size of peptides makes them easier for the body to digest.
お知らせ • Apr 14Hofseth BioCare ASA Publishes Clinical Trial Results of Omego Full Spectrum OmegasHofseth BioCare ASA announced the publication of its head-to-head clinical trial results with its patented, full spectrum omegas brand, OmeGo. The trial showed that OmeGo increased the Omega 3 Index (O3I) by over 70% after 14 weeks, over and above a popular omega-3 supplement brand. It was also markedly more effective at reducing inflammatory markers (hsCRP, TNFa and IL-6) which are closely related to the development of ill health. The omega-3 index (O3I) assesses the level of EPA and DHA in red blood cells – a measure known to correlate well with the overall amount of omega-3 in the body. An optimal O3I level has been shown to reduce the risk of death from any cause by around 35%. Indeed, a higher O3I is associated with a reduced risk of major killers including cardiovascular and metabolic disease and cancer. Notably, OmeGo contains 2.5 times less EPA & DHA than the omega-3 supplement comparator used in this study. However, its natural food matrix significantly enhances OmeGo’s bioavailability. Hence its full spectrum profile better replicates the well-known health benefits associated with regularly eating fish. The success of this clinical study directly challenges the prevailing market assumption that higher-dose concentrated fish oils deliver greater health benefits. This represents a paradigm shift in how omega potency is viewed in the nutraceuticals market.
お知らせ • Dec 04Hofseth BioCare ASA, Annual General Meeting, May 22, 2026Hofseth BioCare ASA, Annual General Meeting, May 22, 2026.
お知らせ • Dec 03+ 4 more updatesHofseth BioCare ASA to Report Fiscal Year 2025 Final Results on Mar 27, 2026Hofseth BioCare ASA announced that they will report fiscal year 2025 final results on Mar 27, 2026
お知らせ • Nov 21Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 29.999999 million.Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 29.999999 million. Security Name: Shares Security Type: Common Stock Securities Offered: 16,666,666 Price\Range: NOK 1.8 Transaction Features: Rights Offering
お知らせ • Oct 27+ 1 more updateHofseth BioCare ASA announced that it expects to receive NOK 103.399999 million in funding from GCI CSS (Hofseth & Nevera) LLCHofseth BioCare ASA announced private placement of 57,444,444 common shares at a price of NOK 1.80 for gross proceeds of NOK 103,399,999.2 on October 27, 2025. The transaction includes participation from Guy Urquhart for 55,444,444 Shares, for gross proceeds of approximately NOK 99,799,999.2 and GCI Hofseth Llc. for 2,000,000 shares for gross proceeds of approximately NOK 3,600,000. The transaction is expected to close on October 30, 2025. The transaction is approved by board of directors of the company and the issuance of shares is subject to Board resolution to allocate shares, Registration of the share capital increase, Satisfaction of contingencies related to the divestment of shares in AecorBio. Upon completion of the Private Placement, the Company will have a share capital of NOK 48,289,214.40, divided by 482,892,140 Ordinary Shares and 16,000,000 unlisted preference shares in Class B held by Hofseth International AS, each with a par value of NOK 0.01.
お知らせ • Sep 10Hofseth Biocare ASA Releases a Whitepaper Demonstrating How Its Bioactive Peptide Ingredient ProGo®? uniquely Provides Complete GLP-1 SupportHofseth Biocare ASA released a whitepaper demonstrating how its bioactive peptide ingredient ProGo®? uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs to be protected to optimize the benefits of weight loss and support a healthy metabolism. ProGo®? addresses these needs through its unique triple action properties: highly absorbable protein with a complete amino acid profile to help build muscle; antioxidant and anti-inflammatory bioactivity to protect muscle health; inhibition of Activin A and Myostatin, negative regulators of muscle mass. ProGo®? is the only commercially available bioactive peptide health ingredient that is both a GLP-1 RA (Receptor Agonist) and has a targeted mode of action for muscle protection via inhibition of Myostatin & Activin A. A fully traceable, high-quality nutritional supplement comprised of hydrolysed peptides and collagen, it has a complete amino acid profile that includes high levels of branched chain amino acids (BCAA) - essential for muscle formation and health. ProGo®? also has a higher bioavailability than other peptides on the market, as the smaller average size of peptides makes them easier for the body to digest.
お知らせ • Sep 04Hofseth BioCare ASA Appoints Paul Bruhn as Head of New Business DevelopmentHofseth BioCare ASA announced the appointment of Paul Bruhn as Head of New Business Development. Mr. Bruhn has over 25 years’ experience in healthcare and the medical nutrition space spanning Novartis Medical Nutrition and Nestle Health Science. He has been leading businesses across multiple geographies including Japan, Korea, India, Middle East, Singapore, Canada, Switzerland and Australia and hence has an excellent overlap with corporates focused on developing the next generation of products targeting clinical nutrition and consumer healthcare. Mr. Bruhn has significant experience working within the medical nutrition, VMS and meal replacement categories, across multiple channels.
お知らせ • Nov 11Hofseth BioCare ASA, Annual General Meeting, May 23, 2025Hofseth BioCare ASA, Annual General Meeting, May 23, 2025.
お知らせ • Nov 09Hofseth BioCare ASA to Report Q4, 2025 Results on Feb 13, 2026Hofseth BioCare ASA announced that they will report Q4, 2025 results at 12:00 PM, Central European Standard Time on Feb 13, 2026
お知らせ • Nov 08+ 3 more updatesHofseth BioCare ASA to Report First Half, 2025 Results on Aug 22, 2025Hofseth BioCare ASA announced that they will report first half, 2025 results on Aug 22, 2025
お知らせ • Oct 22Hofseth Biocare Asa Announces Resignation of Christel Elise Kanli as CFOHofseth BioCare ASA announced that Christel Elise Kanli has decided to step down as Chief Financial Officer (CFO) of the company to pursue opportunities outside of the company.
お知らせ • Mar 15Hofseth BioCare ASA Announces Board ChangesHofseth BioCare ASA announced Kristin Fjellby Grung, Chair of the Board has informed the Board of Directors that she will resign from the position on 31 March 2024, as she will assume a position as judge in the District Court of Møre and Romsdal and will therefore not be able to continue to serve in the position as Chair of the Board. Grung has been a member of the Board of Directors since December 2020, and assumed the position as Chair in April 2022. The Board would like to thank Grung for her services for Hofseth BioCare in this period. Appointment of a new Chair of the Board will be proposed to the Company's annual general meeting, to be held on 10 May 2024. In the interim period, Roger Hofseth will function as the Chair of the Board of Directors.
お知らせ • Nov 14+ 5 more updatesHofseth BioCare ASA to Report Q4, 2024 Results on Feb 14, 2025Hofseth BioCare ASA announced that they will report Q4, 2024 results on Feb 14, 2025
お知らせ • May 31Hofseth Biocare ASA Announces the Online Publication of Its AbstractHofseth Biocare ASA announced the online publication of its abstract titled "Antiproliferative activity of marine-derived oligopeptides combined with androgen receptor inhibition in preclinical cancer models" (Journal of Clinical Oncology 41, 2023, supplement 16; abstract # e15186) ahead of the annual ASCO meeting in Chicago, June 2-5, 2023. This work by HBC represents the final phase of invitro research which has identified the lead peptide candidates, FT-002 and FT-005, for organoid and in vivo prostate cancer research in combination with standard of care therapy, planned to commence during H2 2023. Prostate cancer remains the most commonly diagnosed cancer in men. Whilst most cases do not shorten life expectancy, advanced prostate cancer remains largely incurable. Hormone therapy remains the cornerstone of treatment however eventually tumours find ways of overcoming treatment and start to grow and spread. One important route of tumour escape is via hijacking cellular iron metabolism. In preclinical models, including those published in the ASCO abstract, FT-002 and FT-005 have shown a consistent ability to modulate iron metabolism within tumour cells to both enhance tumour cell sensitivity to standard of care hormone therapy as well as reversing resistance to standard hormone therapy.
お知らせ • Nov 18+ 4 more updatesHofseth BioCare ASA to Report Fiscal Year 2022 Results on Mar 31, 2023Hofseth BioCare ASA announced that they will report fiscal year 2022 results on Mar 31, 2023
